Healthcare

Its copper-based imaging and therapy candidates for prostate cancer have produced a steady run of trial updates, manufacturing agreements and regulatory designations. Even so, the stock trades at a fraction of its September 2024 high near A$8.98, and well below the A$4.20 at which …

Both halves now sit before the market: the strongest distribution outcome the company has secured, and the tightest funding position it has reported.

LTR Pharma (ASX:LTP) is a pharmaceutical development company focused on advancing SPONTAN, a nasal-spray treatment targeting the erectile-dysfunction market.

Paradigm Biopharmaceuticals (ASX:PAR) is a clinical-stage biotechnology company focused on developing treatments for conditions with significant unmet medical needs.

Sonic Healthcare Ltd (ASX: SHL) attracted investor attention after its shares closed on 28 July 2026 at $22.01, rising 2.85% during the session. The stock gained $0.61 on the day, adding to its recent momentum with a weekly increase of 7.79%.

• Ramsay Health Care Ltd (ASX: RHC) shares closed on 28 July 2026 at $43.40, rising 2.02% or $0.86 during the session.• The stock recorded a weekly gain of 0.70% and remains up 11.74% over the past year.• Ramsay Health Care operates within the …

• Dimerix acquired DMX-652, an oral once-daily USP30 inhibitor for acute kidney injury, from Mission Therapeutics for US$5 million upfront plus potential milestone payments of up to US$287 million.